Yours, Mine, or Ours? Navigating Intellectual Property Ownership in the Non-Profit Life Sciences

September 17, 2019 8:00 AM - 10:00 AM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

Add to Calendar 9/17/2019 8:00:00 AM 9/17/2019 10:00:00 AM Yours, Mine, or Ours? Navigating Intellectual Property Ownership in the Non-Profit Life Sciences

Providing a new therapy or medical device to patients who will benefit generally requires commercial development. Development strategies are informed in part by patent laws governing ownership of intellectual property (IP), a complex landscape that must be navigated by non-profit organizations focused on advancing the development of new therapies for unmet medical needs. Join us for a discussion of the opportunities and challenges that non-profit organizations face in developing an IP strategy that will foster their mission effectively. Topics to be considered include:

  • Defining appropriate IP ownership expectations when awarding research grants.
  • Balancing research institution expectations of royalty returns with overall development investments and healthcare costs.
  • Managing conflicts of interest to ensure that patient benefit and safety remain the top priority.
 MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
Senior Advisor, JDRF T1D Fund
Before joining the T1D Fund in 2017, Peter Lomedico spent 11 years working with JDRF Research to establish T1D research collaborations with biotechnology and pharmaceutical companies. Peter has a diverse background in molecular biology, diabetes research and drug discovery, before JDRF he worked at several biotechnology companies (NeoGenesis, CuraGen and Genome Therapeutics) and ran drug discovery and development projects at Hoffmann-La Roche in NJ and Switzerland. Early in his career, Peter conducted diabetes research as a grad student and was a JDRF postdoctoral fellow at Harvard University. He has more than 30 publications and three issued patents. Peter serves on the board for AnTolRx, Inc., a T1D Immunology Company spun off from Harvard Medical School with a JDRF equity investment. Peter has a Ph.D. in molecular biology from the University of Texas Health Science Center at Houston and a B.S. in biology from Villanova University.